Fifteen Novel EIF2B1-5 Mutations Identified in Chinese Children with Leukoencephalopathy with Vanishing White Matter and a Long Term Follow-Up

Haihua Zhang1, Lifang Dai1, Na Chen1, Lili Zang1, Xuerong Leng1, Li Du1, Jingmin Wang1, Yuwu Jiang1, Feng Zhang2, Xiru Wu1, Ye Wu1*

1 Department of Pediatrics, Peking University First Hospital, Beijing, China, 2 School of Life Sciences, Fudan University, Shanghai, China

* dryewu@263.net

Abstract

Leukoencephalopathy with vanishing white matter (VWM) is one of the most prevalent inherited childhood white matter disorders, which caused by mutations in each of the five subunits of eukaryotic translation initiation factor 2B (EIF2B1-5). In our study, 34 out of the 36 clinically diagnosed children (94%) were identified to have EIF2B1-5 mutations by sequencing. 15 novel mutations were identified. CNVs were not detected in patients with only one mutant allele and mutation-negative determined by gene sequencing. There is a significantly higher incidence of patients with EIF2B3 mutations compared with Caucasian patients (32% vs. 4%). c.1037T>C (p.Ile346Thr) in EIF2B3 was confirmed to be a founder mutation in Chinese, which probably one of the causes of the genotypic differences between ethnicities. Our average 4.4 years-follow-up on infantile, early childhood and juvenile VWM children suggested a rapid deterioration in motor function. Episodic aggravation was presented in 90% of infantile cases and 71.4% of childhood cases. 10 patients died during the follow-up. The Kaplan-Meier curve showed that the median survival time is 8.83 ± 1.51 years. This is the largest sample of children in a VWM follow-up study, which is helpful for a more depth understanding about the natural course.

Introduction

Leukoencephalopathy with vanishing white matter (VWM, OMIM306896) is one of the most prevalent inherited leukoencephalopathies in children [1,2]. Inherited in an autosomal recessive manner, VWM is the first known hereditary human disease caused by direct defects in the initiation of the protein translation process, specifically, gene defects in EIF2B1-5, encoding the five subunits of eukaryotic translation initiation factor 2B (eIF2Bα, β, γ, δ and ε) [3,4]. VWM is a progressive disorder clinically dominated by progressive cerebellar ataxia and spasticity. Cognition is relatively preserved, and optic atrophy with loss of vision and epilepsy might occur.
VWM has an extremely wide phenotypic variation and might affect people of all ages, including antenatal, infantile, early childhood, juvenile and adult [8–10]. The most common type of VWM is early childhood type. To date, more than 250 cases and 150 mutations of EIF2B1-5 have been reported [11][12].

Since we reported the first Chinese case of VWM in 2006, a total of 34 Chinese cases have been identified with EIF2B1-5 mutations. Our previous studies have revealed a unique EIF2B1-5 mutation spectrum in Chinese patients, with much higher EIF2B3 incidence than Caucasian population [13]. In this study, we further analyzed the genotype of the 34 Chinese children with VWM, and 15 novel mutations were identified. Natural history was followed up for an average 4.4 years.

Materials and Methods

Patients

The clinical diagnosis of early childhood VWM (onset age 2–6 years) is mainly on the basis of the following criteria [14]. 1) Early psychomotor development is usually normal or mildly delayed; 2) The clinical presentation consists of early-childhood onset of episodic and chronically progressive neurological regression. Episodes of rapid deterioration might be provoked by mild head trauma, febrile infection or fear; 3) Neurological signs mainly consist of cerebellar ataxia and spasticity; and 4) The brain MRI shows diffuse and symmetrical signal in cerebral white matter similar to cerebrospinal fluid on T1-weighted, T2-weighted and flair images (Fig. 1). The diagnosis of infantile (onset before 2 year-of-age) and juvenile (onset later than 6 year-of-age) patients was based on progressive motor regression and brain MRI [15]. Thirty-six clinically diagnosed cases were collected from September 2006 to December 2013 in Peking University First Hospital. All cases were Han Chinese.

This study was approved by the clinical research ethics committee of Peking University First Hospital. Written informed consent was obtained from all of the families on behalf of the children enrolled.

Genotype analysis

EIF2B1-5 gene sequencing. Genomic DNA was extracted from the white blood cells of the children and their parents. The sequence of EIF2B1-5 was obtained from the UCSC Genome Bioinformatics database (EIF2B1: NM_001414; EIF2B2:NM_014239; EIF2B3 NM_020365; EIF2B4:NJ_172195; EIF2B5: NM_003907). The exons and flanking introns were amplified. The novel mutations identified in patients were tested in 100 controls. The pathogenicity of the novel missense mutations were predicted by Software of PolyPhen2, SIFT and Mutation Taster.

CNV analysis. To further analyze the patients with negative sequencing results (including the patients with one mutant allele), Affymetrix SNP 5.0 chip technology was used to detect the presence of copy number variation (CNV), especially the deletions covering the EIF2B1-5.

Founder mutation determination. Among the 11 patients carrying mutations in EIF2B3, 8 (73%) patients harbored at least one copy of the p.Ile346Thr (c.1037T>C) mutation. The nature of the founder mutation was suspected and determined by allele-specific PCR. Fifty-nine SNPs within 2.2 Kb upstream and downstream of the c.1037 were genotyped, and 4 informative SNPs (rs185522, rs188710918, rs184361839, and rs55893665) were found. The forward primer ended either in T or C (rs185522), and a common backward primer was used (Fig. 2). The forward primers used were 5’tcctaggcagaggaccgt3’ or 5’tctaggcagaggaccgtgc3’, and the reverse primer was 5’tgagcctctacctggtttgg 3’. The length of the PCR products was 1.8 Kb. Allele-specific PCR was performed to amplify fragments containing rs188710918, rs184361839
rs55893665, and c.1037. Single alleles containing either the wild type or mutant c.1037 were amplified. To determine whether c.1037T>C is a founder mutation, SNPs within the amplified mutant alleles from the patients were compared.

Fig 1. Brain MRI in VWM children. MRI from an infantile case (A, B, C), an early childhood case (D, E, F) and a juvenile case (G, H, I) respectively. In infantile and early childhood case, diffuse and symmetrical low signal in T1 (A, D), high signal in T2 (B, E) and Flair (C, F) images were shown in cerebral white matter, with part of white matter becomes CSF-like signal (low signal in Flair images). The white matter involvement in the juvenile case is milder, with only periventricular white matter and inner rim of corpus callosum involved and without CSF-like changes.

doi:10.1371/journal.pone.0118001.g001

Fig 2. Primers in allele-specific PCR. The forward primer (in italics) ended either in T or C (rs185522), and a common backward primer (in italics) was used. The length of the PCR products was 1.8 Kb. Allele-specific PCR was performed to amplify fragments containing rs188710918, rs184361839 rs55893665, and c.1037.

doi:10.1371/journal.pone.0118001.g002
Follow-up study

Methods of the follow-up. Thirty-four cases confirmed by gene sequencing were followed-up. Since 2006 when the first VWM child was diagnosed, the number of patients gradually increased. The follow-up was conducted at 2008, 2010 and 2013 respectively. The first time follow-up, second time follow-up and third time follow-up rates were 91.67% (11/12), 82.35% (14/17), and 94.12% (32/34), respectively. During the follow-up, patients were interviewed by telephone (80%), home visits, or outpatient visiting. The analysis focused mainly on the progression of motor impairment, seizures, episodic aggravation, and survival rate. Given the limitations of the follow-up methods, we could not objectively carry on cognitive evaluation for children. Therefore we failed to conduct a detailed assessment of cognitive impairment. For the children who died during the follow-up period, each visit after the death was counted as being followed.

The assessment of motor function was based on the Gross Motor Function Classification System (GMFCS) for cerebral palsy, Chinese version [16]. Levels I-V were classified according to motor function and age. For the patients who acquired the ability to walk, level I was classified as walking independently indoors and outdoors, level II was classified as walking independently but with limitations on uneven surfaces and inclines, level III was classified as walking with assistance, level IV was classified as ambulance using a power wheelchair, and level V was classified as the loss of independent mobility.

Statistics. Each patient had an initial visit and 1–3 follow-up visits. In the analysis and description of motor progression with prolonged disease duration, according to the disease duration of the four time points mentioned above, we divided the children into four groups: disease duration < 3 years, 3–5 years, 5–8 years, and more than 8 years. If the follow-up data at different times for a child crossed groups, the final follow-up results were used.

For survival analysis, age of disease onset in the children was used as the starting point. For children who died during the follow-up period, the death time was the end point. The last follow-up was the end point for the patients being alive. We used a Kaplan-Meier curve to describe the life span, and the statistical analyses of the data were conducted using SPSS16.0 software.

Results

Genotype features of Chinese VWM children

Overall findings. 34 out of the 36 children clinically diagnosed (34/36, 94%) were identified to have EIF2B1-5 mutations by gene sequencing. The patients were compound heterozygous or homozygous, with the mutations inherited from their parents with normal phenotypes. In two patients, mutations were identified in only one allele. Two patients were mutation-negative. Thirty-seven mutations were found in EIF2B1-5, including 33 missense mutations, 1 nonsense mutation, and 3 deletions (1 in-frame and 2 frame-shift mutations) (Table 1). 15 novel mutations were identified. Novel mutations were not found in 100 controls. CNVs were not detected by aCGH in patients with only one mutant allele and mutation-negative determined by gene sequencing.

Constituent ratio of patients and mutations in 5 genes. Among the 34 patients, 12 had mutations in EIF2B5 (35%), 11 had mutations in EIF2B3 (32%), 6 had mutations in EIF2B4 (18%), 4 had mutations in EIF2B2 (12%) and 1 had mutations in EIF2B1 (3%). There is a significantly higher incidence of patients with EIF2B3 mutations compared with Caucasian patients (32% vs. 4%, $\chi^2 = 35.136, p<0.001$) (Table 2)
Table 1. *EIF2B1*-5 mutations in 34 gene-confirmed VWM patients.

| Case | Phenotype        | Gene | Exons | Nucleotide change | Amino-acid change | Novel / reported | Parental derivation | PolyPhen2 (Score) | SIFT (Score) | MutationTaster |
|------|------------------|------|-------|-------------------|-------------------|------------------|---------------------|-------------------|--------------|----------------|
| 1    | early childhood  | EIF2B3 | 2     | c.140G>A         | p.Gly47Glu        | reported         | paternal            | /                 | /            |                |
|      |                  |       | 9     | c.1037T>C        | p.Ile346Thr       | reported         | maternal            | /                 | /            |                |
| 2    | infantile        | EIF2B5 | 7     | c.943C>T         | p.Arg315Cys       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 7     | c.943C>T         | p.Arg315Cys       | reported         | paternal            | /                 | /            |                |
| 3    | infantile        | EIF2B5 | 7     | c.1126A>G        | p.Asn376Asp       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 9     | c.1340C>T        | p.Ser447Leu       | reported         | paternal            | /                 | /            |                |
| 4    | early childhood  | EIF2B5 | 6     | c.805C>T         | p.Arg269*         | reported         | maternal            | /                 | /            |                |
|      |                  |       | 7     | c.1004G>C        | p.Cys335Ser       | reported         | /                   | /                 | /            |                |
| 5    | early childhood  | EIF2B3 | 7     | c.674G>A         | p.Arg225Gln       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 7     | c.674G>A         | p.Arg225Gln       | reported         | paternal            | /                 | /            |                |
| 6    | juvenile         | EIF2B5 | 1     | c.185A>C         | p.Asp62Val        | reported         | paternal            | /                 | /            |                |
|      |                  |       | 7     | c.1016G>C        | p.Arg339Pro       | reported         | maternal            | /                 | /            |                |
| 7    | early childhood  | EIF2B5 | 8     | c.1157G>T        | p.Gly386Val       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 13    | c.1827–1838del   | p.S610-D613del    | reported         | /                   | /                 | /            |                |
| 8    | early childhood  | EIF2B3 | 9     | c.1037T>C        | p.Ile346Thr       | reported         | paternal            | /                 | /            |                |
|      |                  |       | 9     | c.1037T>C        | p.Ile346Thr       | reported         | /                   | /                 | /            |                |
| 9    | infantile        | EIF2B3 | 9     | c.1037T>C        | p.Ile346Thr       | reported         | maternal            | /                 | /            |                |
|      |                  |       |       |                   |                   |                 |                     | /                 | /            |                |
| 10   | early childhood  | EIF2B5 | 3     | c.337C>A         | p.Arg113Cys       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 6     | c.806G>A         | p.Arg269Gln       | reported         | paternal            | /                 | /            |                |
| 11   | early childhood  | EIF2B3 | 9     | c.1037T>C        | p.Ile346Thr       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 9     | c.1037T>C        | p.Ile346Thr       | reported         | paternal            | /                 | /            |                |
| 12   | infantile        | EIF2B2 | 2     | c.254T>A         | p.Val85Glu        | reported         | paternal            | /                 | /            |                |
|      |                  |       | 8     | c.922G>A         | p.Val308Met       | reported         | maternal            | /                 | /            |                |
| 13   | infantile        | EIF2B4 | 10    | c.1180C>T        | p.Leu394Phe       | reported         | /                   | /                 | /            |                |
|      |                  |       | 10    | c.1180C>T        | p.Leu394Phe       | reported         | /                   | /                 | /            |                |
| 14   | early childhood  | EIF2B5 | 6     | c.806G>A         | p.Arg269Gln       | reported         | maternal            | /                 | /            |                |
|      |                  |       | 7     | c.915G>A         | p.Met305Ile       | novel            | /                   | possibly damaging (0.728) | affect protein function (0.00) | disease causing |
| 15   | early childhood  | EIF2B3 | 8     | c.935G>A         | p.Arg312Gln       | novel            | maternal            | /                 | /            |                |
|      |                  |       | 9     | c.1037T>C        | p.Ile346Thr       | reported         | paternal            | /                 | /            |                |
| 16   | infantile        | EIF2B4 | 6     | c.691G>A         | p.Gly231Ser       | novel            | paternal            | /                 | /            |                |
|      |                  |       | 12    | c.1459C>T        | p.Arg487Ser       | reported         | maternal            | /                 | /            |                |
| 17   | early childhood  | EIF2B3 | 9     | c.1037T>C        | p.Ile346Thr       | reported         | paternal            | /                 | /            |                |
|      |                  |       | 10    | c.1106_1113del   | p.S369Sfs*13      | novel            | maternal            | Frameshift        | /            |                |
| 18   | early childhood  | EIF2B5 | 7     | c.943C>T         | p.Arg315Cys       | reported         | paternal            | /                 | /            |                |
|      |                  |       | 7     | c.943C>T         | p.Arg315Cys       | reported         | maternal            | /                 | /            |                |

(Continued)
| Case  | Phenotype     | Gene | Exons | Nucleotide change | Amino-acid change | Novel / reported | Parental derivation | PolyPhen2 (Score) | SIFT (Score) | MutationTaster |
|-------|---------------|------|-------|-------------------|-------------------|------------------|---------------------|-------------------|--------------|----------------|
| 19    | infantile     | **EIF2B5** | 1     | c.185 A>T         | p.Asp62Val       | reported         | maternal            | /                 | /            |                |
| 20    | infantile     | **EIF2B5** | 10    | c.1518delA        | p.E506fs*52      | novel            | paternal            | Frameshift        | /            |                |
|       |               |      | 9     | c.1340 C>T        | p.Ser447Leu      | reported         | maternal            | /                 | /            |                |
| 21    | infantile     | **EIF2B5** | 6     | c.806G>A          | p.Arg269Gln      | reported         | paternal            | /                 | /            |                |
| 22    | juvenile      | **EIF2B4** | 12    | c.1382A>G         | P.Tyr461Cys      | novel            | maternal            | possibly damaging (0.559) | affect protein function (0.00) | disease causing |
|       |               |      | 13    | c.1565C>T         | P.Thr522Met      | novel            | paternal            | probably damaging (1.000) | affect protein function (0.00) | disease causing |
| 23    | early childhood | **EIF2B4** | 12    | c.1306T>A         | p.Ser416Thr      | novel            | paternal            | possibly damaging (0.880) | affect protein function (0.00) | disease causing |
|       |               |      | 12    | c.1397G>A         | P.Arg446His      | novel            | /                   | probably damaging (0.980) | affect protein function (0.00) | disease causing |
| 24    | early childhood | **EIF2B4** | 10    | c.1180C>T         | p.Leu394Phe      | reported         | paternal            | /                 | /            |                |
| 25    | early childhood | **EIF2B3** | 9     | c.1037T>C         | P.Ile346Thr      | reported         | maternal            | /                 | /            |                |
| 26    | infantile     | **EIF2B3** | 2     | c.32G>T           | p.Gly111Val      | reported         | paternal            | /                 | /            |                |
| 27    | juvenile      | **EIF2B2** | 6     | c.818A>G          | p.Lys273Arg      | reported         | /                   | /                 | /            |                |
| 28    | early childhood | **EIF2B2** | 8     | c.922 G>A         | p.Val308Met      | reported         | maternal            | /                 | /            |                |
| 29    | early childhood | **EIF2B1** | 4     | c.328A>G          | p.Lys110Glu      | novel            | /                   | probably damaging (0.973) | affect protein function (0.00) | disease causing |
|       |               |      | 4     | c.328A>G          | p.Lys110Glu      | novel            | maternal            | probably damaging (0.973) | affect protein function (0.00) | disease causing |
| 30    | early childhood | **EIF2B2** | 2     | c.254T>A          | p.Val85Glu       | reported         | maternal            | /                 | /            |                |
|       |               |      | 6     | c.818A>C          | p.Lys273Gln      | reported         | /                   | /                 | /            |                |

(Continued)
Founder mutation in EIF2B3 confirmed. Among the 11 patients who carried mutations in EIF2B3, 8 cases (73%, 8/11) harbored at least one copy of the p.Ile346Thr (c.1037T>C). The SNPs of the mutant allele amplified by allele specific PCR were compared among the 8 patients. We found that all of the mutant alleles in these patients shared the same SNPs surrounding the mutation, with t for rs185522, g for rs188710918, t for rs184361839, and c for rs55893665. This suggested the nature of the founder mutation.

Natural history. Thirty-four children who were genetically diagnosed were followed up, including 24 males and 10 females. All of the children were unrelated. All of the individuals were children of non-consanguineous parents, except two patients (patient 21 and patient 24).

Table 2. Constitution ratio of patients and EIF2B1-5 mutations.

| Gene | Constitution ratio of patients(%) | Constitution ratio of mutations(%) |
|------|----------------------------------|----------------------------------|
|      | Reported in Caucasian (n = 250) | Chinese (n = 34) | Reported in Caucasians (n = 150) | Chinese (n = 37) |
| EIF2B1 | 1 | 3 | 4 | 3 |
| EIF2B2 | 20 | 12 | 15 | 13 |
| EIF2B3 | 4 | 32 | 7 | 19 |
| EIF2B4 | 10 | 18 | 17 | 22 |
| EIF2B5 | 65 | 35 | 57 | 43 |

Among 37 identified mutations, 16 mutations were in EIF2B5 (43%), 8 in EIF2B4 (22%), 7 in EIF2B3 (19%), 5 in EIF2B2 (13%), and 1 in EIF2B1 (3%).

Table 1. (Continued)
Family history was negative for all but 1 case (patient 4), whose older sister had the similar symptoms and died due to an acute infection of the upper respiratory tract at 2 years of age without definite diagnosis. The phenotype of 34 patients and data of follow-up was described in Table 3.

**Disease onset.** Before the disease onset, developmental milestones were within the normal range in 22 cases (65%, 22/34), and 12 cases had a mild delay in their motor or cognitive development. The average age of disease onset was 2.5 years old (4 months to 9 years 7 months). Twenty-one children met the disease onset age (2–6 years) for the classical early childhood form, 10 children met the onset age (<2 years) for the infantile form, and 3 children met the onset age (6–10 years) for the juvenile form. Twenty-one cases had acute onset (62%, 21/34) after a fever or mild head injury. Thirteen cases suffered subacute onset without obvious incentive. At the first visit, the chief complaint was motor deterioration in all of the children but one, who suffered from convulsions and unconsciousness.

**Progressive motor deterioration.** At the first visit, the average disease duration was 1.1 years (5 months to 7 years 3 months). Eleven (91.67%) out of 12 genetically diagnosed cases were being followed up for the first time, 14 out of 17 (82.35%) genetically diagnosed cases were being followed up for the second time, and 32 out of 34 (94.12%) genetically diagnosed cases were being followed up for the third time. The average disease duration was 2.8 years (9 months-7 years 4 months), 4.0 years (5 months-8 years 9 months), and 4.4 years (3 months-12 years), respectively. The motor function was progressively impaired in all of the patients. Individuals were classified into 4 groups according to their disease duration at the first visit and each follow-up. There were 28 cases with disease duration less than three years, and 23 of those patients were still alive. Twelve cases had disease duration of 3–5 years, and only 8 of those patients were surviving. Thirteen cases had disease duration of 5–8 years, and 11 patients were surviving. Five cases had disease duration more than 8 years, and 3 of those children were still alive. For the surviving children, when the disease duration is less than three years, approximately half of the children still walk independently (GMFCSI-II), 21.7% of the children lost their ability of walking, confined to wheelchair or bedridden (GMFCSIV-V). For the children with disease duration 3–5 years, only 1/4 of the children could still walk independently, and 37.5% of the children were classified as GMFCSIV or V. For the children with disease duration 5–8 years, only 9.1% could still walk independently. All of the survival children with disease duration more than eight years were confined to wheelchair or bedridden. (Fig. 3)

**Survival analysis.** By the time of the last follow-up, 10 patients (31.2%) died, including 7 infantile cases and 3 early childhood cases. The average age of death in infantile cases was 2.4 years (8months-4years 10months), with average disease duration of 1.2 years (2 months-3 years 8 months). Three early childhood cases died 2.8, 8 and 8.8 years after the disease onset respectively. The age of death was 4.8, 10 and 12 years old respectively. All of the patients died from rapid deterioration after recurrent infections. Survival curve analysis was conducted in the 32 cases at the last follow-up. Ten patients died, and 22 cases were censored. The Kaplan-Meier curve showed that the 1-year survival rate is 93.2%, the 3-year survival rate is 80.7%, the 5-year survival rate is 70.6%, the 8-year survival rate is 63.5%, and the 10-year survival rate is 47.7% (Fig. 4). The median survival time is 8.83 ± 1.51 years.

**Episodic aggravation.** Episodic aggravation precipitated by fever or mild head trauma was observed in 24 cases (70.6%, 24/34), including 9 infantile cases (90.0%, 9/10) and 15 early childhood cases (71.4%, 15/21). The three juvenile cases did not present episodic aggravation during the follow-up. In the condition of acute episode, children showed rapid motor deterioration, which sometimes led to a comatose state. After removing the aggravating cause, there would be gradual improvement but generally could not be restored to the state before the exacerbation.
Table 3. The follow-up of 34 gene-confirmed Chinese VWM patients.

| Cases | Gender | DD | Disease onset | Disease duration (y) | Symptoms and signs | First visit | Disease duration (y) | Symptoms and signs | First Follow-up (2008) | Disease duration (y) | Symptoms and signs | Second Follow-up (2010) | Disease duration (y) | Symptoms and signs | Third Follow-up (2013) | Disease duration (y) | Symptoms and signs | Episodic aggravation |
|-------|--------|----|--------------|----------------------|--------------------|-------------|----------------------|--------------------|------------------------|----------------------|--------------------|------------------------|----------------------|--------------------|------------------------|----------------------|--------------------|----------------------|
| 1     | F      | _  | 3y subacute  | 1.00                 | II                 | 3.58        | IV,S                 | 6.5                 | V,S                   | 8.83                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 2     | M      | +  | 1y4m subacute| 0.50                 | III                | 3.5         | V,S                 | 3.67                | death                 | 6.00                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 3     | M      | _  | 1y6m acute   | 1.41                 | I                  | 3.5         | III,S               | 6.25                | IV,S                  | 8.5                  | V,S                |                        |                      |                     |                        |                      |                     | +                    |
| 4     | F      | _  | 2y acute     | 5.41                 | IV                 | 7.33        | IV,S                 | 8                   | death                 | 11.98                | death              |                        |                      |                     |                        |                      |                     | +                    |
| 5     | M      | +  | 3y8m acute   | 0.17                 | I                  | 2.67        | III                 | 4.34                | IV                    | 6.67                 | V                 |                        |                      |                     |                        |                      |                     | +                    |
| 6     | M      | _  | 6y5m subacute| 0.24                 | I                  | 1.83        | II,S                | 3.58                | III                   | 5.91                 | V,S                |                        |                      |                     |                        |                      |                     | -                    |
| 7     | M      | _  | 4y acute     | 0.50                 | III                | 1.92        | III                 | 4.42                | III                   | 6.75                 | IV,S               |                        |                      |                     |                        |                      |                     | +                    |
| 8     | M      | _  | 3y9m acute   | 0.42                 | I                  | 1.75        | III                 | 5.42                | IV                    | 7.75                 | IV,S               |                        |                      |                     |                        |                      |                     | +                    |
| 9     | M      | +  | 1y6m subacute| 0.50                 | I,S                | 1.5         | IV                  | 4                   | V                     | /                    | /                 |                        |                      |                     |                        |                      |                     | +                    |
| 10    | F      | _  | 2y5m acute   | 0.25                 | I                  | 0.76        | II                  | /                   | /                     | 5.50                 | IV,S               |                        |                      |                     |                        |                      |                     | +                    |
| 11    | M      | _  | 4y3m acute   | 0.75                 | I                  | 0.92        | II                  | 2.75                | III                   | 5.08                 | IV                |                        |                      |                     |                        |                      |                     | +                    |
| 12    | F      | _  | 1y1m acute   | 0.09                 | I                  | /           | /                   | 1.59                | death                 | 3.92                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 13    | M      | _  | 1y8m acute   | 0.17                 | I                  | UA          | UA                  | /                   | /                     | /                    | /                 |                        |                      |                     |                        |                      |                     | +                    |
| 14    | F      | _  | 4y6m acute   | 7.25                 | IV                 | UA          | UA                  | 8.75                | IV                    | 11.08                | V,S               |                        |                      |                     |                        |                      |                     | +                    |
| 15    | M      | _  | 2y acute     | 1.17                 | II                | UA          | UA                  | 1.42                | IV                    | 3.75                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 16    | M      | +  | 4m subacute  | 0.09                 | I                  | UA          | UA                  | /                   | /                     | 3.17                 | death              |                        |                      |                     |                        |                      |                     | _                    |
| 17    | M      | _  | 2y3m acute   | 0.33                 | I                  | UA          | UA                  | 0.42                | IV                    | 2.75                 | IV                |                        |                      |                     |                        |                      |                     | +                    |
| 18    | M      | _  | 2y6m acute   | 0.25                 | I                  | UA          | UA                  | 1.25                | IV                    | 1.50                 | III               |                        |                      |                     |                        |                      |                     | +                    |
| 19    | F      | +  | 1y10m acute  | 0.17                 | IV                 | UA          | UA                  | UA                  | UA                    | 1.33                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 20    | M      | +  | 7m acute     | 0.17                 | I,S                | UA          | UA                  | UA                  | UA                    | 0.50                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 21    | F      | _  | 1y7m acute   | 0.17                 | IV                 | UA          | UA                  | 1.18                | death                 | 1.58                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 22    | M      | _  | 9y7m subacute| 0.17                 | I                  | UA          | UA                  | UA                  | UA                    | 0.33                 | I                 |                        |                      |                     |                        |                      |                     | +                    |
| 23    | M      | +  | 5y acute     | 0.08                 | I                  | UA          | UA                  | UA                  | UA                    | 2.08                 | II                |                        |                      |                     |                        |                      |                     | _                    |
| 24    | M      | _  | 5y subacute  | 0.33                 | I                  | UA          | UA                  | UA                  | UA                    | 2.00                 | II                |                        |                      |                     |                        |                      |                     | _                    |
| 25    | F      | +  | 3y acute     | 1.00                 | III                | UA          | UA                  | UA                  | UA                    | 2.08                 | V                 |                        |                      |                     |                        |                      |                     | +                    |
| 26    | F      | +  | 1y5m acute   | 0.04                 | IV                 | UA          | UA                  | UA                  | UA                    | 1.00                 | death              |                        |                      |                     |                        |                      |                     | +                    |
| 27    | M      | +  | 7y6m acute   | 0.08                 | II                 | UA          | UA                  | UA                  | UA                    | 1.50                 | II                |                        |                      |                     |                        |                      |                     | _                    |
| 28    | M      | _  | 3y subacute  | 2.00                 | I                  | UA          | UA                  | UA                  | UA                    | 2.33                 | II,S              |                        |                      |                     |                        |                      |                     | _                    |
| 29    | F      | _  | 2y2m acute   | 0.08                 | IV                 | UA          | UA                  | UA                  | UA                    | 1.25                 | V,S               |                        |                      |                     |                        |                      |                     | +                    |
| 30    | F      | _  | 3y subacute  | 4.58                 | II                 | UA          | UA                  | UA                  | UA                    | 10.66                | IV,S              |                        |                      |                     |                        |                      |                     | +                    |
| 31    | F      | _  | 2y6m subacute| 4.33                 | I                  | UA          | UA                  | UA                  | UA                    | 7.75                 | II,S              |                        |                      |                     |                        |                      |                     | _                    |
| 32    | F      | _  | 2y1m subacute| 0.58                 | III                | UA          | UA                  | UA                  | UA                    | 0.75                 | III               |                        |                      |                     |                        |                      |                     | _                    |
| 33    | F      | _  | 3y7m subacute| 0.09                 | I                  | UA          | UA                  | UA                  | UA                    | 0.25                 | I                 |                        |                      |                     |                        |                      |                     | _                    |
| 34    | F      | _  | 5y subacute  | 1.84                 | II                 | UA          | UA                  | 1.84                | IV                    | 5.92                 | IV                |                        |                      |                     |                        |                      |                     | +                    |

DD: developmental delay; F: female; M: male; UA: unavailable; /: loss to follow-up; S: seizure; I-V: GMFCSI-V

doi:10.1371/journal.pone.0118001.t003
Sixteen patients (50%, 16/32) experienced seizures (with or without fever) during the study, including 12 (75%) early childhood cases and 4 (25%) infantile cases. The seizures usually occurred 1–2 years after the disease onset. The frequency of seizures was once per week to once per year. All of the children showed focal seizures, without status epilepticus. The seizures were usually easily controlled with antiepileptic drugs.

**Discussion**

VWM is one of the most prevalent inherited childhood white matter disorders. A wide range of mutations in each of the five subunits of eukaryotic translation initiation factor 2B (eIF2B1-5) could lead to this fatal neurodegenerative disease [2]. eIF2B is a complex of five subunits (eIF2Bα, β, γ, δ, and ε). Guanine nucleotide-exchanging factor (GEF) activity to catalyze the eIF2-bound GDP–GTP exchange is necessary for protein translation initiation, and eIF2Be is the most important subunit [17–19]. The remaining subunits play key roles in the regulation of
the GEF activity of eIF2Bε. Gene defects in \( \text{EIF2B}1-5 \) inhibit the conversion of eIF2-GDP to eIF2-GTP, resulting in the disruption of protein translation initiation [20–23]. It is suggested that mutant eIF2B resulted in improper activation of unfolded protein response (UPR) in the condition of endoplasmic reticulum stress, which has been proven in fibroblasts or lymphoblasts from VWM patients, and oligodendrocytes from VWM mouse model [24–27]. \( \text{EIF2B}1-5 \) are housekeeping genes playing essential roles in various type of cells [28][29], why only the white matter involved is not understood yet.

Since the five causative genes were identified in 2001–2002[3][4], over 250 patients and 150 mutations have been reported. In previous studies from Caucasian patients, the most frequent mutations are in the \( \text{EIF2B}5 \) (which contains 57% of all of the mutations), mutations in the \( \text{EIF2B}4 \) and \( \text{EIF2B}2 \) gene follow, with 16% and 16%, respectively. Mutations in \( \text{EIF2B}3 \) account for 7% the mutations, and mutations in \( \text{EIF2B}1 \) account for 4% of the mutations [30][31]. In Caucasian patients, approximately 65% of the patients have mutations in \( \text{EIF2B}5 \), 20% have mutations in \( \text{EIF2B}2 \), 10% have mutations in \( \text{EIF2B}4 \), 4% have mutations in \( \text{EIF2B}3 \) and 1% have mutations in \( \text{EIF2B}1 \) [25] (Table 2).

We confirmed the first case of VWM in China in 2006. To date, a total of 34 Chinese cases have been genetically diagnosed in our pediatric neurological center. The positive rate of gene sequencing in clinically diagnosed VWM children is 94% (34/36). Thirty-seven mutations have been found. Of these mutations, 89% (33/37) are missense mutations, consistent with previous reports [11][32]. Frame-shift and nonsense mutations are rare and often occur in the compound-heterozygous state, which consistent with previous reports [31][31][33–35]. 15 novel mutations were identified, expanding the \( \text{EIF2B}1-5 \) mutation spectrum significantly. The most striking finding in our study is that there is a significantly higher incidence of patients with \( \text{EIF2B}3 \) mutations compared with Caucasian patients (32% vs. 4%, \( \chi^2 = 35.136, p<0.001 \)). This finding provided a genetic testing strategy for Chinese VWM patients, which means that
**EIF2B5** and **EIF2B3** should be tested first if a traditional sequencing method is used. Since 2013, targeted next-generation exome sequencing has been used in our clinical practice, which helped us to sequence the five genes simultaneously.

In our study, CNVs were not detected in any patients with only one mutant allele or mutation-negative determined by gene sequencing. Shimada S reported a child with phenotype of VWM and multiple malformations who had one copy deletion at the region of 14q24.3 (75,059,408–77,069,618, 2.0 Mb), covering 25 genes including **EIF2B2**, and another heterozygous missense mutation in **EIF2B2** on the other allele [36]. We did not identify any mutations of the **EIF2B1-5** genes in two clinically diagnosed cases (5.6%, 2/36). We hypothesize that mutations located in the non-coding regions of **EIF2B1-5** or other undiscovered causative genes might exist.

We noticed that among the 11 patients who carried mutations in **EIF2B3** (encoding eIF2Bγ), 8 cases (73%, 8/11) harbored at least one copy of the p.Ile346Thr (c.1037T>C) mutation. It was confirmed to be a founder mutation in Chinese patients. Founder mutations are a special class of genetic mutations embedded in stretches of DNA that are identical in all of the people who have the mutation [37]. Everyone with a founder mutation has a common ancestor, the founder, in whom the mutation first appeared. The 8 cases had different surnames. Five of the patients were from northern provinces in China, and 3 were from the southern provinces. Hundreds of years ago, their families probably shared a founder ancestor. p. Thr91Ala in **EIF2B5** has been identified as the founder mutation in Netherlands and North American [38]. The founder mutation might be one of the important causes of the genotypic differences between ethnicities. The mutation p. Arg113His in **EIF2B5** occurs in almost 40% of Caucasian VWM patients [31], and it was thought to be a hot spot mutation. However, it was not identified in the any Chinese patients in our study. Therefore probably it is a founder mutation in Caucasian people.

It is known that episodic aggravation is a prominent clinical manifestation in VWM, but the incidence in infantile and childhood VWM patients is unclear. Labauge P reported that 38% of the adult VWM patients suffered episodic aggravation [39]. In our cases series, 90% of the infantile and 71.4% of the early childhood patients suffered episodic aggravation, suggesting that episodic aggravation is more common in infantile and early childhood VWM. Episodic aggravation was not observed in the three juvenile cases. We cannot rule out the possibility that episodic aggravation appeared later due to the limited number of the cases and the short disease duration.

To assess the motor function, we performed detailed follow-up and analysis. The results suggest that motor function in Chinese VWM children deteriorates rapidly. For the surviving children with the disease duration less than three years, approximately half could still walk independently, and 21.7% of the children score GMFCSIV-V. In the group with disease duration 5–8 years, only 9.1% of the children could still walk independently. In the group with disease duration more than 8 years, all of the survival children were confined to wheelchair or bed. Fogli A estimated motor function in VWM with the Kaplan–Meier method, and the study showed that at 10 years of disease evolution, 95% of infantile cases and 75% of early childhood cases would suffer severe disability (individual required constant supervision, confined to bed or loss of cognitive abilities) [40]. The motor function deteriorated more rapidly in Chinese VWM children, which is probably related to the lack of formal rehabilitation training and social supports after the diagnosis in most of cases.

There were no detailed studies regarding the survival rate and lifespan of VWM patients. It was reported that patients diagnosed in early childhood would die in the second decade of disease evolution [15]. In the present study, 10 patients died by the last follow-up, including 70% (7/10) of infantile cases with an average disease duration of 1.2 years and 14% (3/21) of early...
childhood cases who died 2.8 years, 8 years and 8.8 years after disease onset, suggesting that earlier disease onset is correlated with shorter survival time. The Kaplan-Meier curve showed that 5-year survival rate was 70.6%, the 8-year survival rate was 63.5%, and the 10-year survival rate was 47.7%. The median survival time was 8.83 ± 1.51 years. The direct causes of death were rapid deterioration in the condition of infections and nutritional disorders, suggesting that nursing conditions, living environment, nutritional support, and social support are the important factors influencing the patients’ survival time.

This study has some limitations. 1) Because the disease currently has no treatment, most of the parents were unwilling to return for visits from a long distance. Telephone contact, which might be biased, is the main way to assess patients’ motor function during the follow-up. And cognitive function evaluation was unavailable. 2) Because of the limited number of cases, we performed an overall assessment of motor function and survival analysis. Grouping the patients according to the age of onset would be better. With the collection of more cases, we will perform more in-depth analyses and more comprehensive follow-up.

Conclusions
This is the largest sample of children in a VWM follow-up study, which is helpful for a more depth understanding about the children’s natural course of the disease. 15 novel mutations of the EIF2B1-5 significantly expanded the mutation spectrum of this disease. The proportion of EIF2B3 mutations in Chinese patients is much higher than the proportion in Caucasian patients, which we assume is related to a founder mutation. There are a small number of clinically diagnosed cases that do not have an EIF2B1-5 gene mutation, suggesting that there might be other genes involved.

Acknowledgments
We thank the patients and their parents. This work was supported by the Natural Science Foundation of China (81171065, 30872793), the National Key Technology R&D program (2012BAI09B00), and the Key Laboratory Program of the Ministry of Education (2012-RG/ND-0001).

Author Contributions
Conceived and designed the experiments: JW YJ XW YW. Performed the experiments: HZ L. Dai NC LZ XL L. Du. Analyzed the data: HZ L. Dai NC FZ YW. Contributed reagents/materials/analysis tools: HZ. Wrote the paper: HZ YW.

References
1. van der Knaap MS, Breiter SN, Naidu S, Hart AAM, Valk J (1999). Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology 213: 121–133. PMID: 10540652
2. Bugiani M, Boor I, Powers JM, Scheper GC, van der Knaap MS (2010) Leukoencephalopathy with vanishing white matter: a review. J Neuropathol Exp Neurol 69: 987–996. doi:10.1097/NEN.0b013e3181f2eafa PMID: 20838246
3. Leegwater PA, Vermeulen G, Köstn AA, Naidu S, Mulders J, et al. (2001) Subunits of the translation initiation factor elf2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 29: 383–388. PMID: 11704758
4. van der Knaap MS, Leegwater PA, Köstn AA, Visser A, Naidu S, et al. (2002) Mutations in each of the five subunits of translation initiation factor elf2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol 51: 264–270. PMID: 11835986
5. van der Knaap MS, Barth PG, Gabrêês FJ, Franzoni E, Begeer JH, et al. (1997) A new leukoencephalopathy with vanishing white matter. Neurology 48: 845–855. PMID: 9108666
6. Schiffmann R, Moller JR, Trapp BD, Shih HH, Farrer RG, et al. (1994) Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol 35: 331–340. PMID: 8122885

7. Hanefeld F, Holzbach U, Kruse B, Wilichowski E, Christen HJ, et al. (1993) Diffuse white matter disease in three children: An encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy. Neuropediatrics 24: 244–248. PMID: 8309512

8. van der Knaap MS, Kamphorst W, Barth PG, Kraaijveld CL, Gut E, et al. (1998) Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 51: 540–547. PMID: 9710032

9. Fogli A, Dionisi-Vici C, Deodato F, Bartuli A, Boespflug-Tanguy O, et al. (2002) A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to EIF2B5 mutation. Neurology 59: 1966–1968. PMID: 12499492

10. van der Knaap MS, van Berkel CG, Herms J, van Coster R, Baethmann M, et al. (2003) eIF2B related disorders: antenatal onset and involvement of multiple organs. Am J Hum Genet 73: 1199–1207. PMID: 14566705

11. Maletkovic J, Schiffmann R, Gorospe JR, Gordon ES, Mintz M, et al. (2008) Genetic and clinical heterogeneity in eIF2B-related disorders. J Child Neurol 23: 205–215. doi: 10.1177/0883073807308705

12. Proud CG (2012) Vanishing white matter: the next 10 years. Future Neurol 7: 81–92.

13. Wu Y, Pan Y, Du L, Wang J, Gu Q, et al. (2009) Identification of novel EIF2B mutations in Chinese patients with vanishing white matter disease. J Hum Genet 54: 74–77. doi: 10.1038/jhg.2008.10 PMID: 19158808

14. van der Knaap MS, Barth PG, Gabrèils FJ, Franzoni E, Begeer JH, et al. (1997) A new leukoencephalopathy with vanishing white matter. Neurology Apr 48(4): 845–855. PMID: 9109866

15. van der Knaap, Pronk JC, Scheper GC (2006) Vanishing white matter disease. Lancet Neurol 5: 413–423. PMID: 16632312

16. Shi W, Wang SJ, Yang H, Zhu M, Wang L, et al. (2006) Study on reliability and validity of the Chinese version of the gross motor function classification system for cerebral palsy. Chin J Evld Based Pediatr 1: 122–129.

17. Pavitt GD (2005) eIF2B, a mediator of general and gene-specific translational control. Biochem Soc Trans 33: 1487–1492. PMID: 16246152

18. Lorsch JR, Dever TE (2010) Molecular view of 43 S complex formation and start site selection in eukaryotic translation initiation. J Biol Chem 285: 21203–21207. doi: 10.1074/jbc.R110.119743 PMID: 20444698

19. Hinnebusch AG (2011) Molecular mechanism of scanning and start codon selection in eukaryotes. Microbiol Mol Biol Rev 75: 434–467. doi: 10.1128/MMBR.00008-11 PMID: 21885680

20. Pavitt GD, Yang W, Hinnebusch AG (1997) Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2. Mol Cell Biol 17: 1298–1313. PMID: 9032257

21. Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731–745. doi: 10.1016/j.cell.2009.01.042 PMID: 19239892

22. Kimball SR, Fabian JR, Pavitt GD, Hinnebusch AG, Jefferson LS (1998) Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha- and delta-subunits of eIF2B. J Biol Chem 273: 12841–12845. PMID: 9582312

23. Elsby R, Heiber JF, Reid P, Kimball SR, Pavitt GD, et al. (2011) The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus. J Virol 85: 9716–9725. doi: 10.1128/JVI.05146-11 PMID: 21795329

24. Horzinski L, Kantor L, Huyghe A, Schiffmann R, Elroy-Stein O, et al. (2010) Evaluation of the endoplasmic reticulum-stress response in eIF2B-mutated lymphocytes and lymphoblasts from CACH/VWM patients. BMC Neurol 10: 94. doi: 10.1186/1471-2377-10-94 PMID: 20958979

25. Kantor L, Harding HP, Ron D, Schiffmann R, Kaneski CR, et al. (2005) Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients. Hum Genet 118: 99–106. PMID: 16041584

26. van Kollenburg B, Thomas AA, Vermeulen G, Bertrand GA, van Berkel CG, et al. (2006) Regulation of protein synthesis in lymphoblasts from vanishing white matter patients. Neurobiol Dis 21: 496–504. PMID: 16185687

27. Kantor L, Pinchas D, Mintz M, Hathour Y, Vanderver A, et al. (2008) A point mutation in translation initiation factor 2B leads to a continuous hyper stress state in oligodendroglial-derived cells. PLoS One 3: e3783. doi: 10.1371/journal.pone.0003783 PMID: 19023445
28. Spilka R, Ernst C, Bergler H, Rainer J, Flechsig S, et al. (2014) eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr) 37:253–67. doi: 10.1007/s13402-014-0181-9 PMID: 25070653
29. Spilka R, Ernst C, Mehta AK, Haybaeck J (2013) Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett 28:9–21.
30. Scali O, DiPerr C, Federico A (2006) The spectrum of mutations for the diagnosis of vanishing white matter disease. Neurol Sci 27:271–277. PMID: 16998732
31. Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS (2006) Vanishing white matter disease: a review with focus on its genetics. Ment Retard Dev Disabil Res Rev 12: 123–128. PMID: 16807905
32. Fogli A, Schiffmann R, Hugendubler L, Combes P, Bertini E, et al. (2004) Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. Eur J Hum Genet 12: 561–566. PMID: 15054402
33. Fogli A, Rodriguez D, Eymard-Pierre E, Bouhour F, Labauge P, et al. (2003) Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 72: 1544–1550. PMID: 12707859
34. Fogli A, Boespflug-Tanguy O (2006) The large spectrum of eIF2B-related diseases. Biochem Soc Trans 34: 22–29. PMID: 16246171
35. Ohlenbusch A, Henneke M, Brockmann K, Goerg M, Hanefeld F, et al. (2005) Identification of ten novel mutations in patients with eIF2B-related disorders. Hum Mutat 25: 411–452. PMID: 15776426
36. Shimada S, Miya K, Oda N, Watanabe Y, Kumada T, et al. (2012) An unmasked mutation of EIF2B2 due to submicroscopic deletion of 14q24.3 in a patient with vanishing white matter disease. Am J Med Genet A 158A: 1771–1777. doi: 10.1002/ajmg.a.35431 PMID: 22678813
37. Drayna D (2005) Founder mutations. Sci Am 293: 78–85. PMID: 16196257
38. van der Lei HD, van Berkel CG, van Wieringen WN, Brenner C, Feigenbaum A, et al. (2010) Genotype-phenotype correlation in vanishing white matter disease. Neurology 75(17): 1555–1559. doi: 10.1212/ WNL.0b013e3181f9f62ae PMID: 20975056
39. Labauge P, Horzinski L, Ayrganac X, Blanc P, Vukusic S, et al. (2009) Natural history of adult-onset eIF2B-related leukodystrophies. Neurology 62: 1509–1517. PMID: 15136673